Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
2nd June 2026 Uncategorised 0
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer

More: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Source: News
